Funding

Research Grant Announced for Herpes Simplex Vaccine

Published in Vaccine Weekly, June 8th, 1998

Cel-Sci Corp., Alexandria, Virginia, announced the receipt of a phase I $100,000 research grant to fund further animal studies with its herpes simplex vaccine.

The grant was given pursuant to the Small Business Innovation Research Program (SBIR) of the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

Daniel Zimmerman, Cel-Sci Corp., said, "We have shown protection against herpes simplex infectivity in animals. Our ultimate goal is to bring to market a preventive and therapeutic vaccine against herpes simplex infection in humans for which there is no approved vaccine or curative treatment available."

The vaccine...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1998-06-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry